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 Improving clinical trial design for 
inquiries into the mechanisms of 
cyst growth in ADPKD 
 Arlene B.  Chapman 1 
 Accurate and reliable estimates of kidney and cyst volume, the hallmark 
of disease progression in ADPKD are now available. These powerful and 
exciting tools make it possible to consider both short and long term 
randomized clinical trials in ADPKD at various stages of disease. 
Highlights of the work by Kistler and colleagues are now provided. 
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Accuracy, precision, and reliability of 
renal and cyst volume measures in 
human ADPKD
 
 Estimates of total renal and cyst volume 
based on magnetic resonance (MR) without 
gadolinium demonstrate high accuracy, 
precision, and reliability throughout a broad 
range of renal volumes in autosomal domi-
nant polycystic kidney disease (ADPKD). 
Kistler and colleagues 1 (this issue) present 
a meticulous and elegantly executed study 
of MR-based renal and cyst volume esti-
mates over time in human ADPKD. Manual 
measurements with trained readers dem-
onstrated >0.99 concordance coeA  cients 
for inter- and intrareader variability for total 
renal volume and slightly less (0.944) for 
total cyst volume. * ese ( ndings are similar 
to those of the Consortium for Radiologic 
Imaging Studies in Polycystic Kidney Dis-
ease (CRISP) study 2 (inter-reader variability 
2.1 % and intrareader variability 2.4 % for 
renal volume), in which gadolinium was 
used. High accuracy, precision, and reliabil-
ity without gadolinium enhancement allow 
for the bene( t of reduced cost of imaging 
and remove the potential risk of developing 
nephrogenic systemic ( brosis. 
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 Renal volume measurements in the 
study by Kistler  et al. 1 were completed 
with the use of manual segmentation by 
trained personnel supported with soO -
ware. * e investigators acknowledge that 
manual segmentation requires signi( cant 
effort and is therefore restricted from 
widespread use. Manual segmentation 
precludes clinical implementation for 
patients with ADPKD, and a high priority 
to develop sophisticated image analysis 
software to support more automated, 
accurate and reliable renal and cyst vol-
ume measurement is needed in ADPKD. 
Development of such technology would 
allow clinicians to focus on patients at 
high risk for progression to renal failure 
and provide valuable predictive informa-
tion to their patients. 
 Cyst volume measurements in this study 
were performed using stereological meth-
ods in T2-weighted images, similar to the 
methods used for renal volume estimates 
in the CRISP study. 2 Intra- and interob-
server variability was similar to that found 
in CRISP, without the use of gadolinium. 
However, estimations of noncystic 
parenchyma without gadolinium are not 
feasible, and this may be an important 
consideration in the evaluation of disease 
progression in ADPKD. 3 In addition, esti-
mates of renal function, using contrast-
enhanced MR imaging, a novel functional 
application of renal MR imaging, 4 are also 
not possible in this setting. 
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 Potentially the largest source of varia-
bility of renal volume estimates in 
ADPKD was not determined in this study. 
* e CRISP study preliminarily addressed 
day-to-day variability of renal and cyst 
volume within ADPKD individuals by 
studying four patients on four occasions. 
Relatively low day-to-day variability 
(2.4 % ) was found with the use of gadolin-
ium-enhanced images. * ese individuals 
were repeatedly studied over relatively 
short intervals (approximately 2 weeks 
between studies), 5 indicating that the 
day-to-day variability of renal volume in 
ADPKD is signi( cantly less than other 
biologically relevant variables such as 
blood pressure and renal function. How-
ever, given the safety issues and cost sav-
ings related to gadolinium use, day-to-day 
variability of renal volume without gado-
linium needs to be addressed more fully 
in larger numbers of patients over shorter 
periods of time at varying stages of hydra-
tion and dehydration. 
 Using renal volume as an outcome 
measure in randomized clinical trials in 
ADPKD: study design considerations 
 Kistler  et al. 1 provide additional informa-
tion regarding the frequency and cadence 
of medical complications related to 
ADPKD and renal volume. A signi( cant 
association between clinical complications 
of ADPKD and renal volume was found. 
Increased renal volume was associated 
with greater frequency of hypertension, 
macro hematuria, urinary tract infections, 
and recurrent flank pain. Importantly, 
10 % of participants demonstrated a sig-
ni( cant reduction in renal volume over 6 
months. * ese individuals demonstrated 
greater baseline renal volumes and more 
complications related to ADPKD than 
those who did not demonstrate a dramatic 
reduction in renal volume. Understanding 
the frequency of these events, as well as 
potential contributors (for example, a rap-
idly increasing rate of cyst or renal 
growth), provides critical information for 
establishing inclusion criteria for enroll-
ment into randomized clinical trials in 
ADPKD as well as considerations for ana-
lytical approaches that account for these 
events during trial participation. Given 
the dramatic volumetric e7 ect of sponta-
neous cyst involution or rupture, subjects 
at high risk for disease progression may be 
inadvertently excluded depending on the 
inclusion criteria used. 
 Although Kistler and colleagues 1 dem-
onstrate that MR measurements every 
6 months are suA  cient to demonstrate 
a detectable change in renal volume in 
ADPKD, caution is warranted in consid-
ering this duration of participation in a 
randomized clinical trial. If one anticipates 
that a therapeutic agent has a signi( cant 
impact (for example, 25 % reduction in the 
rate of cyst or renal expansion), assessing 
change in renal and cyst volume over a 
6-month duration will be insuA  cient to 
detect real therapeutic e7 ects. * is mag-
nitude of change is potentially less than 
the level of detection with current MR-
based imaging protocols. On the basis 
of volumetric measures in the study 
by Kistler  et al. 1 and the CRISP study, 
only half of the subjects could be included 
in a 6-month study where this magnitude 
of e7 ect is anticipated, and many indi-
viduals with progressive renal disease 
would be excluded. 
 Given the complex nature of cyst 
growth in ADPKD, such as alterations in 
epithelial proliferation, rates of apoptosis, 
extracellular matrix responses, and the 
presence of cyst K uid secretion, multiple 
agents targeting di7 erent aspects of cyst 
growth and expansion will most likely be 
used in ADPKD. * e duration of drug 
exposure to determine whether therapeu-
tic impact is possible will vary on the 
basis of the aspect of cyst growth and for-
mation targeted. Investigators will need 
to take into account the pace at which 
these alterations contribute to cyst growth 
in ADPKD. For example, inhibition of the 
renin – angiotensin system may provide 
therapeutic benefit for renal and cyst 
growth in ADPKD over a relatively long 
period of time where tissue ( brosis and 
vascular remodeling are chronically 
affected. Alternatively, with agents 
that acutely alter cyst K uid secretion, such 
as secretin or somatostatin analogues, 
shorter and intermittent exposures may 
be suA  cient to demonstrate a bene( cial 
effect. For those interventions that 
a7 ect epithelial proliferation or apoptosis 
(such as mTOR inhibitors), exposure 
time may need to be intermediate to 
determine eA  cacy. 
 Risk strati= cation for disease progression 
using renal volume estimates in ADPKD 
 * e study by Kistler  et al. , 1 as well as the 
CRISP study, highlights the important 
fact that ADPKD patients at high risk for 
progression can now be identi( ed by MR-
based measures. Renal volume can pro-
vide a strati( cation to high or low risk for 
disease progression in ADPKD. In the 
study by Kistler  et al. , 1 those with the 
greatest renal volume demonstrated the 
fastest rate of increase in renal size. In 
addition, the greatest renal volume was 
associated with the greatest frequency of 
complications in ADPKD, including the 
frequency of hypertension, the presence 
of albuminuria, and the frequency of epi-
sodes of gross hematuria and asympto-
matic cyst rupture. * e lessons of Kistler 
 et al. 1 show that it is reasonable to justify 
renal volume as a marker of disease sever-
ity and progression in ADPKD. Young 
ADPKD patients with large renal volumes 
demonstrate the most rapid progression 
of disease and should be identified as 
high-risk ADPKD patients. Importantly, 
the magnitude of renal volume change 
correlates with initial renal volume 
throughout the study population, 
but most strongly in the younger-than-
30-year age group. 
 Mechanisms responsible for cyst and 
renal growth in ADPKD 
 In both this and the CRISP study, an 
extremely high level of agreement between 
leO  and right kidney volume was found. 
In addition, both studies demonstrated a 
strong association between change in leO  
and change in right kidney volume over 
time. * is level of agreement between kid-
neys within individuals where random 
somatic mutations or second hits are 
required for cyst development is diA  cult 
to reconcile. Only a small proportion of 
individuals demonstrated signi( cantly 
discordant renal volumes, and many of 
these were the individuals who developed 
asymptomatic cyst rupture. Heritability 
indices of renal volume in healthy controls 
have not been established with MR, but in 
ADPKD, heritability indices are extremely 
high, greater than 85 % . 6 * e high correla-
tion between leO  and right renal volumes 
in CRISP and the study by Kistler  et al. 1 
suggests that heritability of renal size in 
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ADPKD is extremely high. Although 
somatic mutations or modi( er inK uences 
play a signi( cant role in disease progres-
sion in ADPKD, studies addressing the 
allelic contribution to disease severity 
( PKD1 or  PKD2 mutations) deserve fur-
ther attention. 
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